Cure My Disease

Don't miss your cure!

 Log in / Sign up

New NASH drug shows promise in early trial

NCT ID NCT06297434

Disease control Sponsor: J2H Biotech Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tested a new drug called J2H-1702 in 87 adults with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. The goal was to see if the drug is safe and if it can reduce liver fat and scarring after 12 weeks compared to a placebo. Participants were randomly assigned to receive either the drug or a dummy pill, and neither they nor their doctors knew which they got.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

87 people

The number who actually took part.

Started

Feb 2023

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. A subject aged ≥19 years to ≤75 years 2. Meeting all of the following criteria: * Screening MRI-PDFF with ≥8% steatosis * Screening MRE with liver stiffness ≥2.5 kPa * ALT or AST ≤250 IU/L at screening 3. Willing to maintain the same lifestyle (exercise, alcohol consumption, diet, etc.) during the study 4. Voluntarily provide written consent to participate in the study Exclusion Criteria: 1. A subject who has past or current history of liver diseases 2. A subject who has the following medical or surgical history * Severe cardiac diseases, Malignant tumors, Clinically significant hypersensitivity reaction to any drugs containing components of the 11β-HSD1 inhibitor or same class 3. A subject who has the following concomitant diseases * liver disease, uncontrolled hypertension, uncontrolled DM, etc. 4. A subject who has taken the following medications * Systemic glucocorticoids, NSAIDs, any medication that may induce fatty liver disease, etc. 5. A subject who has taken IP of another study 6. A subject who does not agree with appropriate methods of contraception

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non - alcoholic steatohepatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non - alcoholic steatohepatitis

Contacts and locations

Locations

  • Chung Ang university hospital

    Seoul, South Korea

  • Dong-A University Hospital

    Busan, South Korea

  • Gyeongsang National University Hospital

    Gyeongsang, South Korea

  • Hallym University Dongtan Sacred Heart Hospital

    Gyeonggi-do, South Korea

  • Hallym University Sacred Heart Hospital

    Gyeonggi-do, South Korea

  • Hanyang University Hospital

    Seoul, South Korea

  • Inha University Hospital

    Incheon, South Korea

  • Kyung Hee University Hospital

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Seoul St. Mary's Hospital

    Seoul, South Korea

  • Soonchunhyang University Seoul Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.